Clinical Observation Of Jiawei Tongxie Yaofang In The Treatment Of Diarrhea-type Irritable Bowel Syndrome With Liver Depression And Spleen Deficiency Syndrome

Objectives:To observe the clinical efficacy of Jiawei Tongxie Yaofang in the treatment of diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency syndrome,objectively evaluate its effectiveness and safety,and provide new effective for clinical treatment.Methods:Sixty-two patients with diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency who met the inclusion criteria were randomly divided into treatment group and control group,with 31 cases in each group.Among them,the treatment group was treated with Jiawei Tongxie Yaofang,the control group was treated with trimebutine maleate tablets,and a course of treatment for 7 days was continued for 28 days.In the course of the study,the patients were not prescribed according to the relevant reasons,and 3 patients who did not meet the requirements were excluded.Finally,59 patients were effective,29 in the treatment group and 30 in the control group.The HAMA scores,TCM clinical symptom scores and recurrence rates of the two groups were observed and evaluated.The safety and clinical efficacy of Jiawei Tongxie prescription in the treatment of IBS-D were evaluated.Result:(1)Comparison of gender and age distribution: The pre-treatment data of the two groups of patients were statistically analyzed: P>0.05,indicating no statistical significance and comparable.(2)Comparison of HAMA scores:On the HAMA total scores of the two groups,the reduction of the HAMA score in the treatment group was 12.31±4.20,and the reduction in the HAMA score of the control group was 8.83±3.07,indicating that the treatment group had a lower HAMA score than the control group.In the two groups of patients with HAMA score reduction rate and total effective rate,the total effective rate of the treatment group was 72.41%,higher than the total effective rate of the control group of 43.33%,indicating that the Jiawei Tongxie Yaofang treatment group improved the HAMA score and efficacy It is superior to the control group and can relieve the anxiety or depression of the patient more effectively.(3)Comparison of TCM symptom scores: In the total scores of TCM symptoms,the total score of TCM symptoms in the treatment group was 8.24±3.76,and the total score of TCM symptoms in the control group was 6.13±2.74,indicating that the treatment group was significantly better than the control group in improving the total score of TCM symptoms.In the analysis of the curative effect of TCM symptoms,the total rate of treatment group was 86.20%,which was higher than the total effective rate of the control group(63.33%),indicating that Jiawei Tongxie prescription is more superior in improving clinical symptoms.(4)Safety aspects:There were no special changes in the safety indicators during the treatment of the two groups,and no adverse events or allergic reactions occurred.(5)Comparison of recurrence rate: The recurrence rate of Jiawei Tongxie Yaofang group was 6.90%,and the recurrence rate of Qumeibu tablets was 26.67%.It can be seen that the prescription of Jiawei Tongxie is better than the long-term treatment of IBS-D in patients with IBS-D,which can reduce the recurrence rate.Conclusion:Jiawei Tongxie Yaofang has a good curative effect and safety in the treatment of diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency syndrome.It can effectively relieve symptoms,has long-term curative effect and has clinical application value.